Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1B Trial on Escalating Doses of Memantine in Down Syndrome

NCT07531940 is registered in ClinicalTrials.gov with University Hospitals Cleveland Medical Center as lead sponsor.

NCT NCT07531940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07531940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1B Trial on Escalating Doses of Memantine in Down Syndrome
Lead sponsor
University Hospitals Cleveland Medical Center
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 14, 2026
Completion date
May 31, 2028
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer dementia (ad), down syndrome, intellectual disability